COVID-19: Nasal and Salivary Detection of the SARS-CoV-2 Virus After Antiviral Mouthrinses

COVID-19: Nasal and Salivary Detection of the SARS-CoV-2 Virus After Antiviral Mouthrinses: Double-blind, Randomized, Placebo-controlled Clinical Study

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04352959

Acronym

BBCovid

Enrollment

176

Registered

2020-04-20

Start date

2020-04-27

Completion date

2020-12-11

Last updated

2021-02-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID19, Mouthwash, Saliva

Keywords

covid19, SARS-CoV-2, mouthrinses, antiviral, bêta-cyclodextrin, citrox

Brief summary

Given the current lack of effective COVID-19 treatment, it is necessary to explore alternative methods to contain the spread of the infection, focusing in particular on its mode of transmission. The modes of person-to-person transmission of SARS-CoV-2 are direct transmission, such as sneezing, coughing, transmission through inhalation of small droplets, and transmission through contact, such as contact with nasal, oral and eye mucous membranes. SARS-CoV-2 can also be transmitted directly or indirectly through saliva. The use of antiviral mouthrinses may be used as adjunctive therapy.

Interventions

DEVICEmouthrinse with bêta-cyclodextrin and citrox

3 daily mouthrinses for 7 days

DEVICEmouthrinse without bêta-cyclodextrin and citrox

3 daily mouthrinses for 7 days

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 85 Years

Healthy volunteers

Inclusion criteria

* Clinical diagnosis of Covid-19 infection by the patient's general practitioner and hospital doctor * Clinical signs started less than 8 days ago. * Virological confirmation * Understanding and acceptance of the trial. * Written agreement to participate in the trial

Exclusion criteria

* Pregnancy * Breastfeeding * Inability to comply with protocol * Lack of written agreement

Design outcomes

Primary

Measure	Time frame	Description
Change from Baseline amount of SARS-CoV-2 in salivary samples at 7 days	7 days	Quantitative PCR experiments will be performed and a quantitative analysis of the salivary samples will be made

Secondary

Measure	Time frame	Description
Change from Baseline amount of SARS-CoV-2 virus in nasal samples at 7 days	7 days	Quantitative PCR experiments will be performed and a quantitative analysis of the nasal samples will be made

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 25, 2026